4Leunissen KML. Impairment of liver synthetic fuction and decreased liver flow during cyclosporine A therapy. Transp Proc, 1987,19 : 1822.
5Akhlaghi F,Trull AK. Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet, 2002,41 ( 9 ): 615-637.
6Palomero J,Galan AI,Munoz ME,et al.S-adenosyl-methionine protects against intrabiliary glutaithione degradation induced by long-term administration of cyclosporin A in the rat.Toxicology,2004,201(1-3): 239-245.
7Khoschrorur G,Aure T,Lanzer G,et al,The determination of metabolite and its meaning for immumosuppressive cyclosprin therapy.Angiology, 1998,49 ( 1 ): 307.
8Taylor PJ.Therapeutic drug monitoring of immunosuppressant drugs by high-performance liquid chromatography-mass spectrometry.Ther Drug Monit, 2004,26( 2 ) :215-219.
9Nagamura F, Takahashi T,Takeuchi M, et al. Effect of cy-clophosphamide on serum cyclosporine levels at the con-ditioning of hematopoietic stem cell transplantation[J].Bone Marrow Transplant, 2003,32( 11) : 1 051.
10Seifeldin R.Drug interactions in transplantation[J].Clin Ther,1995,17(6):1 043.
